Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial

BACKGROUND: The NEAT001/ANRS143 trial demonstrated noninferiority of ritonavir-boosted darunavir combined with either raltegravir (RAL + DRV/r) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC + DRV/r) in HIV-positive, antiretroviral-naive adults. In post hoc analyses, however, RAL + DRV/r sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ammassari, Adriana, Stöhr, Wolfgang, Antinori, Andrea, Molina, Jean-Michel, Schwimmer, Christine, Domingo, Pere, Thalme, Anders, Di Pietro, Massimo, Wallet, Cedrick, Pozniak, Anton, Richert, Laura, Raffi, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250251/
https://www.ncbi.nlm.nih.gov/pubmed/30365452
http://dx.doi.org/10.1097/QAI.0000000000001834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250251/
https://www.ncbi.nlm.nih.gov/pubmed/30365452
http://dx.doi.org/10.1097/QAI.0000000000001834

Ejemplares similares